Clinical Trial Update: Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating ACT-128800 for efficacy, safety, and tolerability in relapsing-remitting multiple sclerosis; results were posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• ACT-128800

Snippet

Sponsor: Actelion | Conditions: Multiple Sclerosis | Phase 2 | Status: COMPLETED | Results posted: 2021-06-11